Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


Traditional clinical trial design in oncology of grouping together patients based on their cancer type has a high attrition rate, with an estimated 95% of potential anticancer drugs failing during development. Researchers are constantly working on ways to overcome this, and one method which is gaining popularity is a “basket” study, grouping together patients by mutation type rather than disease.

Read more

The health risks of smoking are well publicized – as well as causing around 90% of lung cancers and many other cancer types, smoking can also trigger lung, heart, and circulatory diseases. The most recent survey from the US showed that 43% of smokers had tried to quit in the past year, but without medication or other help, only 4% to 7% had managed to give up at any given attempt. Electronic cigarettes (e-cigarettes) are the newest product available in the fight to quit smoking, yet little is known about whether they really work and their health benefits and risks. As regulatory agencies around the world start to take more control over e-cigarettes we review the burning questions around...

Read more

July 15, 2014

Dying for a Suntan?


With summer here again, many people will be jetting off to sunny locations to top up their tans. Public health campaigns have had a lot of success in encouraging sunbathers to wear sunscreen, to cut down their UV exposure and protect themselves from skin cancer. However, newly published research has shown that sunscreen alone can only delay, not prevent, melanoma, a particularly dangerous skin cancer type.

Read more

Crown Bioscience attended the 74th Scientific Sessions of the American Diabetes Association (ADA) last month in San Francisco. When we weren’t manning our booth or presenting our scientific results (with all our posters incorporating the latest Layar technology) we found time to review the research on display. One poster which caught our attention presented data on hepatitis B vaccination reducing the risk of diabetes, which provides another talking point in the already crowded hepatitis and diabetes research world.

Read more

Every research scientist dreams of publishing a Nature or Science paper, making a ground breaking discovery in their field and impacting on future research around the world. One of the main questions in Oncology is “what happens next”? How is high impact research turned in to improved therapeutic options?

Read more

The FDA has approved MannKind’s Afrezza® at the third time of asking, making it the first inhaled insulin available for people with diabetes since Exubera® in 2006. As Crown Bioscience reviewed last month, the path to FDA approval has not been an easy one, with concerns over efficacy, safety, and inhaler design. While this approval is great news for people living with diabetes, MannKind still have to prove to patients and doctors that their therapy is not just a lot of hot air.

Read more